Top 10 Asian Companies To Watch For 2015

September 16, 2013: U.S. markets opened higher Monday morning after an announcement on Sunday by Larry Summers that he was withdrawing his name from consideration as the next chairman of the Federal Reserve. Summers was seen as more likely to end the Fed��s asset purchase program quickly than is Janet Yellen, who is now the betting favorite to be the new Fed chair. U.S. markets closed mixed as Apple Inc. (NASDAQ: AAPL) dragged the tech sector and the Nasdaq Composite down. Longer term, though, Apple might not look so bad.

Asian and European markets closed mostly higer today, while Latin American markets closed mixed.

Tuesday��s calendar includes the beginning of the two-day FOMC meeting and the following data releases and events (all times Eastern):

8:30 a.m. – Consumer price index 9:00 a.m. – Treasury international capital (TIC) data 10:00 a.m. – Housing market index 11:30 a.m. – 4- and 52-week bill auctions

Here are the closing bell levels for Monday:

Hot Shipping Stocks For 2016: Receptos Inc (RCPT)

Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company��s product candidates span three specialty disease areas. The Company��s lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.

As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.

As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company��s second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal antibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune-mediated disorder.

Advisors' Opinion:

• [By Ben Levisohn]

  Yes, say the folks at Nomura, who recommend buying�Celgene (CELG), Receptos
  (RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:

• [By Garrett Cook]

  Receptos (NASDAQ: RCPT) shares shot up 46.35 percent to $99.14 after the company announced positive Phase 2 results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis.

• [By Garrett Cook]

  Receptos (NASDAQ: RCPT) shares shot up 38.62 percent to $93.90 after the company announced positive Phase 2 results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis.

Top 10 Asian Companies To Watch For 2015: WisdomTree SmallCap Earnings Fund (EES)

WisdomTree SmallCap Earnings Fund (the Fund) seeks investment results that correspond to the price and yield performance of the WisdomTree SmallCap Earnings Index (the Index). The Index is a fundamentally weighted index that measures the performance of earnings-generating companies within the small-capitalization segment of the United States stock market. The Index consists of the companies in the bottom 25% of the market capitalization of the WisdomTree Earnings Index after the 500 largest companies have been removed. Companies must be incorporated and listed in the United States, and must have generated positive cumulative earnings over their most recent four fiscal quarters prior to the Index measurement date. The Index is earnings-weighted in December to reflect the proportionate share of the aggregate earnings each component company has generated. Companies with greater earnings generally have larger weights in the Index. Its investment advisor is WisdomTree Asset Management, Inc. Advisors' Opinion:

• [By Philip Springer]

  WisdomTree SmallCap Earnings Fund (EES) follows earnings generated by companies in the small-cap universe of the US stock market.

  Furthermore, the fund looks to weight by earnings, giving bigger weights to firms that earn more, irrespective of market capitalization.

Top 10 Asian Companies To Watch For 2015: Blackbaud Inc.(BLKB)

Blackbaud, Inc. provides software and related services for nonprofit organizations. The company offers The Raiser?s Edge, a software application to manage constituent relationship management (CRM) and fundraising activity; Blackbaud CRM, a Web-based CRM solution that addresses the needs of mid-size, large, and federated chapter based nonprofit organizations; eTapestry, a software-as-a-service (SaaS) donor management and fundraising solution for smaller nonprofits; Blackbaud NetCommunity, an Internet marketing and communications tool to build interactive Websites and manage email marketing campaigns; Sphere eMarketing, a SaaS that provides applications to manage e-marketing, communications, programs, services, and online fundraising; Everyday Hero, an event-based online fundraising solution; and BlackbaudNow for developing an online presence and accepting online donations. It also provides The Financial Edge, an accounting application; The Education Edge, a student informa tion management system; Blackbaud?s Student Information System, which links student information across various campus offices, as well as organizes the admissions and registrar?s processes; and Blackbaud for Small Schools, a SaaS solution that helps schools with their registration process, as well as gives parents, students, and faculty an online access to school information. In addition, the company offers The Patron Edge, a ticketing management solution; Blackbaud Direct Marketing that helps in managing direct marketing campaigns with various media and channels; Sphere Friends Asking Friends software product to launch and manage online event fundraising Websites; and Altru, a SaaS solution that helps general admissions arts and cultural organizations in their operation. Further, it provides consulting and education, analytics, maintenance, and payment processing services. Blackbaud, Inc. was founded in 1981 and is headquartered in Charleston, South Carolina.

Advisors' Opinion:

• [By Seth Jayson]

  Blackbaud (Nasdaq: BLKB  ) is expected to report Q1 earnings on May 1. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Blackbaud's revenues will expand 20.7% and EPS will expand 11.8%.

• [By MONEYMORNING.COM]

  Now we like Blackbaud Inc. (NasdaqGS: BLKB).

  Charleston, S.C.-based Blackbaud focuses on such nonprofits as research foundations and universities. The company has 29,000 clients who use its software to manage fundraising, accounting, and online marketing and payment services.

Top 10 Asian Companies To Watch For 2015: BB&T Corp (BBT)

BB&T Corporation (BB&T) is a financial holding company. BB&T conducts its business operations primarily through its commercial bank subsidiary, Branch Banking and Trust Company (Branch Bank), which has offices in North Carolina, Virginia, Florida, Georgia, Maryland, South Carolina, Alabama, West Virginia, Kentucky, Tennessee, Texas, Washington D.C and Indiana. In addition, BB&T��s operations consist of a federally chartered thrift institution, BB&T Financial, FSB (BB&T FSB), and a number of nonbank subsidiaries, which offer financial services products. BB&T��s operations are divided into six business segments: Community Banking, Residential Mortgage Banking, Dealer Financial Services, Specialized Lending, Insurance Services, and Financial Services. Branch Bank provides a range of banking and trust services for retail and commercial clients in its geographic markets, including small and mid-size businesses, public agencies, local Governments and individuals, through 1,779 offices as of December 31, 2011. During the year ended December 31, 2011, BB&T announced the acquisitions of Liberty Benefit Insurance Services, Atlantic Risk Management Corporation and the Precept Group. In April 2012, it acquired the life and property and casualty insurance operating divisions of Roseland, New Jersey - based Crump Group Inc. On July 31, 2012, it acquired BankAtlantic.

As of December 31, 2011, the principal operating subsidiaries of BB&T included Branch Banking and Trust Company, Winston-Salem, North Carolina; BB&T Financial, FSB, Columbus, Georgia; Scott & Stringfellow, LLC, Richmond, Virginia; Clearview Correspondent Services, LLC, Richmond, Virginia; Regional Acceptance Corporation, Greenville, North Carolina; American Coastal Insurance Company, Davie, Florida, and Sterling Capital Management, LLC, Charlotte, North Carolina. Branch Bank��s principal operating subsidiaries include BB&T Equipment Finance Corporation, BB&T Investment Services, Inc., BB&T Insurance Services, Inc., Stanley, Hunt, DuPree! & Rhine (a division of Branch Bank), Prime Rate Premium Finance Corporation, Inc., Grandbridge Real Estate Capital, LLC, Lendmark Financial Services, Inc., CRC Insurance Services, Inc. and McGriff, Seibels & Williams, Inc.

Community Banking

BB&T��s Community Banking serves individual and business clients by offering a range of loan and deposit products and other financial services. As of December 31, 2011, Community Banking had a network of 1,779 banking.

Residential Mortgage Banking

Residential Mortgage Banking segment retains and services mortgage loans originated by Community Banking, as well as those purchased from various correspondent originators. Mortgage loan products include fixed and adjustable rate Government and conventional loans for the purpose of constructing, purchasing or refinancing residential properties. Substantially all of the properties are owner occupied. BB&T retains the servicing rights to all loans sold. Residential Mortgage Banking earns interest on loans held in the warehouse and portfolio, fee income from the origination and servicing of mortgage loans and recognizes gains or losses from the sale of mortgage loans. BB&T��s mortgage originations totaled $23.7 billion in 2011. BB&T��s residential mortgage servicing portfolio, which includes both retained loans and loans serviced for third parties, totaled $91.6 billion in 2011.

Dealer Financial Services

Dealer Financial Services originates loans to consumers on a prime and nonprime basis for the purchase of automobiles. Such loans are originated on an indirect basis through approved franchised and independent automobile dealers throughout the BB&T market area and nationally through Regional Acceptance Corporation. This segment also originates loans for the purchase of boats and recreational vehicles originated through dealers in BB&T��s market area. In addition, financing and servicing to dealers for their inventories is provided through a ! joint rel! ationship between Dealer Financial Services and Community Banking.

Specialized Lending

BB&T��s Specialized Lending consists of eight business units that provide specialty finance products to consumers and businesses. The internal business units include Commercial Finance that contains commercial finance and mortgage warehouse lending; and, Governmental Finance that is responsible for tax-exempt Government finance. Operating subsidiaries include BB&T Equipment Finance which provides equipment leasing within BB&T��s banking footprint; Sheffield Financial, a division of FSB Financial, a dealer-based financer of equipment for both small businesses and consumers; Lendmark Financial Services, a direct consumer finance lending company; Prime Rate Premium Finance Corporation, which includes AFCO and CAFO, insurance premium finance business units that provide funding to businesses in the United States and Canada and to consumers in certain markets within BB&T��s banking footprint, and Grandbridge Real Estate Capital, a commercial mortgage banking lender providing loans on a national basis.

Insurance Services

BB&T Insurance Services provides property and casualty, life and health insurance to businesses and individuals. It also provides small business and corporate products, such as workers compensation and professional liability, as well as surety coverage and title insurance. In addition, Insurance Services also underwrites a limited amount of property and casualty coverage.

Financial Services

Financial Services provides personal trust administration, estate planning, investment counseling, wealth management, asset management, employee benefits services, corporate banking and corporate trust services to individuals, corporations, institutions, foundations and Government entities. Financial Services also offers clients investment alternatives, including discount brokerage services, equities, fixed-rate and variable-rate annuiti! es, mutua! l funds and governmental and municipal bonds through BB&T Investment Services, Inc., a subsidiary of Branch Bank. Financial Services includes Scott & Stringfellow, LLC, a brokerage and investment banking firm. Scott & Stringfellow provides services in retail brokerage, equity and debt underwriting, investment advice, corporate finance and equity research and facilitates the origination, trading and distribution of fixed-income securities and equity products in both the public and private capital markets. Scott & Stringfellow also has a public finance department that provides investment banking services, financial advisory services and municipal bond financing. Scott & Stringfellow��s investment banking and corporate and public finance areas conduct business as BB&T Capital Markets. This segment includes BB&T Capital Partners that is a group of BB&T-sponsored private equity and mezzanine investment funds that invest in privately owned middle-market operating companies. Financial Services also includes the Corporate Banking Division that originates and services corporate relationships, syndicated lending relationships and client derivatives.

Advisors' Opinion:

• [By Michael Flannelly]

  Goldman Sachs analysts upgraded financial services company BB&T Corporation (BBT) on Tuesday because the stock offers an upside to earnings in a rising interest rate environment.

  The analysts upgraded BBT from “Neutral” to “Buy” and see shares reaching $39, up from the previous target of $37. This new price target suggests a 13% upside to the stock’s Monday closing price of $34.48.

  The analysts cited three main factors for the upgrade. For one, as mentioned above, BB&T offers an upside to earnings in a rising interest rate environment because it is leveraged to the long-end of the yield curve. Also, the analysts expect the company’s credit losses to continue to improve. Finally, the analysts expect BB&T’s loan growth to pick up.

  Moreover, Goldman Sachs boosted BB&T’s fiscal 2013, 2014, and 2015 EPS estimates to $2.50, $3.22, and $3.55, respectively.

  BB&T Corp shares were up 42 cents, or 1.22%, during pre-market trading on Tuesday. The stock is up 18.45% year-to-date.

• [By WWW.DAILYFINANCE.COM]

  AlamyCitizens Bank ranks the No. 1 financial institution among baby boomers. Each stage of life brings with it a unique set of challenges to overcome and benchmarks to hit -- and this is especially true when it comes to banking. Although financial institutions target millennials heavily, baby boomers (Americans born between 1946 and 1964) are still the most represented generation among today's banking customers. A December Gallup poll revealed that 89 percent of baby boomers have at least one checking, savings or money market account. With more than 75 million baby boomers in the United States, there's a greater demand for financial institutions that cater to the boomer lifestyle. 3 Things Baby Boomers Need Most From Banks The youngest baby boomers have reached seniority in the labor force, while the oldest members of this generation have entered retirement. Both ends of the spectrum have vastly different circumstances when it comes to income, but no matter their age, boomers have three main banking needs. 1. Customer Service. Customer service comes in many forms, whether from an in-person associate at a brick-and-mortar branch or an attendant at a small kiosk in a local grocery store. Boomers have grown up with institutions that rely on real-life, person-to-person transactions that allow them to talk through terms and conditions and have questions addressed. Physical bank branches are necessary in order to fulfill this service expectation. As more financial institutions have turned to online and mobile banking, some baby boomers who are slow to adapt to banking technology have been isolated as a result. 2. Retirement Planning. With the average life span in the U.S. expanding each year, and so many baby boomers on the road to retirement, the need for retirement planning resources becomes more and more pressing for many banking customers. "In my experience, the most stressful situation that baby boomers encounter is the fear of running out of money d

• [By Shauna O'Brien]

  Before Thursday’s opening bell, regional bank BB&T Corporation (BBT) reported higher first quarter earnings. Despite the increase in earnings, the company was unable to exceed analysts’ expectations.

  BBT’s Earnings in Brief

  BBT posted first quarter earnings of�$501 million, or 69 cents per share, up from�$210 million, or 29 cents per share, a year ago. Analysts expected to see earnings of 70 cents per share. Revenue for the quarter was�$2.29 billion, down from $2.46 billion last year and below analysts’ estimate of $2.31 billion. The bank reported that its loan portfolio rose 1.7% from the Q1 of last year.

  CEO Commentary

  BBT’s chairman and CEO Kelly S. King had the following comments:�”Our results for the first quarter were solid in light of normal seasonality. Insurance revenues were very strong for the quarter, credit results continued to improve and expenses were down $53 million compared with last quarter, reflecting improving expense control. Commercial loan growth was strong, particularly commercial real estate lending for income producing properties. Consistent with industry trends, mortgage banking income declined as originations were down from last year’s record levels.”

  BBT’s Dividend

  BBT paid its last quarterly dividend of 23 cents on March 3. �The company reported that it is considering raising its dividend to 24 cents. We expect BBT to declare its next dividend sometime in April.

  Stock Performance

  BB&T Corporation shares were mostly flat during pre-market trading Thursday. The stock is up 5.41% YTD.

  BBT Dividend Snapshot

  As of market close of April 16, 2014

  Click here to see the complete history of BBT dividends.

• [By Amanda Alix]

  The best, and the worst
  For the fourth year in a row, BB&T (NYSE: BBT  ) has taken the top spot for the highest consumer approval rating among mortgage servicers -- scoring 765 out of a possible 1,000 points -- though it did register a drop from last year's grade of 803. At the very bottom of the pile, servicers Ocwen and Nationstar still reside: Ocwen improved by 36 points, though Nationstar lost 11 points.

Top 10 Asian Companies To Watch For 2015: Insys Therapeutics Inc (INSY)

Insys Therapeutics, Inc., incorporated on June 15, 1990, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The Company��s pharmaceuticals portfolio consists of one approved product and a number of product candidates targeting cancer-supportive care and cancer therapy. The Company��s product candidate includes Subsys, Dronabinol SG Capsule, Dronabinol RT Capsule, Dronabinol Oral Solution, Dronabinol Inhalation Device, and Dronabinol IV Solution. The Company is also developing cancer therapeutics, which is LEP-ETU, a formulation of paclitaxel, the active ingredient in the cancer drugs Taxol and Abraxane. On August 19, 2011, the Food & Drug Administration (FDA) approved its Dronabinol SG Capsule product, a generic equivalent to Marinol, for the treatment of chemotherapy induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with acquired immune deficiency syndrome (AIDS).

Subsys

The Company's Subsys is a single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue. Subsys is a transmucosal product to show pain relief when measuring the sum of pain intensity difference at five minutes in a Phase 3 breakthrough cancer pain (BTCP) clinical trial using fentanyl.

Dronabinol Product Family

The Company has an approved dronabinol product and is developing several dronabinol product candidates for the treatment of CINV and appetite stimulation in patients with AIDS, as well as other indications where dronabinol could have potential therapeutic benefits. Dronabinol, the active ingredient in Marinol, is a synthetic cannabinoid whose chemical name is delta-9-tetrahydrocannabinol (THC). Its portfolio consists of its Dronabinol SG Capsule product and Dronabinol RT Capsule product candidate, which are intended to be generic equi! valents to Marinol, in addition to three formulations, including Dronabinol Oral Solution. Dronabinol SG Capsule is a dronabinol soft gelatin capsule intended to be a generic equivalent to Marinol. Dronabinol RT Capsule is a dronabinol soft gel capsule that is stable at room temperature. Dronabinol Oral Solution is a ynthetic THC in an oral liquid formulation.

Cancer Therapeutics

In addition to its cancer-supportive care products, the Company intends to develop cancer therapeutics targeting limitations of existing commercial products. LEP-ETU, it advanced cancer therapeutic, is a NeoLipid liposomal, or microscopic membrane-like structure created from lipids, formulation that incorporates paclitaxel. LEP-ETU completed a Phase 2 clinical trial of 70 patients with metastatic breast cancer.

The Company competes with Cephalon, Inc., BioDelivery Sciences International, Inc., ProStrakan Group plc, Nycomed International Management GmbH, Archimedes Pharma Ltd., TEVA Pharmaceuticals USA, Watson Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc., Akela Pharma Inc., Abbott Laboratories, Pharmaceutical International, Inc., Par Pharmaceutical Companies Inc., sanofi-aventis, Eisai Inc., Helsinn Group, Roche Holding AG, Par Pharmaceutical Companies Inc., GlaxoSmithKline plc, ProStrakan Group plc, Merck & Co, GW Pharmaceutical, A.P. Pharma, Inc., Aphios Corp., Roche Holding, Tesaro, Inc., Cornerstone Pharmaceutical, Inc., Bristol-Myers Squibb, Celgene Corporation, Laboratories, Amgen Inc., AstraZeneca PLC., Bayer AG, Biogen Idec Inc., Eisai Co., Ltd., F. Hoffmann- LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Onyx Pharmaceuticals Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Advisors' Opinion:

• [By Monica Gerson]

  INSYS Therapeutics (NASDAQ: INSY) is projected to report its Q1 earnings at $0.28 per share on revenue of $45.63 million.

  Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

• [By Roberto Pedone]

  One specialty pharmaceutical player that's quickly moving within range of triggering a big breakout trade is Insys Therapeutics (INSY), which develops and commercialize supportive care products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. This stock is off to a monster start in 2013, with shares up a whopping 434%.

  >>5 Stocks Insiders Love Right Now

  If you take a look at the chart for Insys Therapeutics, you'll notice that this stock has been uptrending strong for the last six months, with shares soaring higher from its low of $9.30 to its recent high of $53.64 a share. During that uptrend, shares of INSY have been making mostly higher lows and higher highs, which is bullish technical price action. Shares of INSY have recently pulled back to its 50-day moving average and the stock has now started to spike higher off that level. That spike is starting to push shares of INSY within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in INSY if it manages to break out above some near-term overhead resistance levels at $43.50 to $44.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 235,266 shares. If that breakout hits soon, then INSY will set up to re-test or possibly take out its next major overhead resistance levels at $47.25 to its all-time high at $53.64 a share.

  Traders can look to buy INSY off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $38.75 a share or near its 50-day at $36.73 a share. One can also buy INSY off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Jake L'Ecuyer]

  INSYS Therapeutics (NASDAQ: INSY) was also down, falling 15.14 percent to $27.73 after news broke that a doctor had fraudulently prescribed its drug Subsys.

• [By Matt Jarzemsky]

  Among companies that went public in the U.S. last year, FireEye has seen the second-biggest share rally since its IPO, trailing only pharmaceutical company Insys Therapeutics Inc.(INSY)

Top 10 Asian Companies To Watch For 2015: China Jo-Jo Drugstores Inc.(CJJD)

China Jo-Jo Drugstores, Inc. owns and operates a retail pharmacy chain in the People?s Republic of China. Its stores sell various medicinal products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicine products, personal care products, family care products, and medical devices, as well as convenience products including consumable, seasonal, and promotional items. The company also has licensed doctors, who provide consultation, examination, and treatment of common ailments. In addition, its stores include medical clinics that offer urgent care, traditional Chinese medicines, and minor outpatient surgical treatments. The company operates a chain of approximately 55 drugstores under the Jiuzhou Grand Pharmacy Quannuo Grand Pharmacy, and Lydia Grand Pharmacy brand names. The company is headquartered in Hangzhou, the People?s Republic of China.

Advisors' Opinion:

• [By Bryan Murphy]

  Although the market seems to be losing traction, and even losing ground now, the same can't be said of every single stock. A handful of stocks like China Jo-Jo Drugstores Inc. (NASDAQ:CJJD), Vuzix Corp. (OTCBB:VUZI), and Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) are forging ahead, doling out gains against the grain. Not that moving higher while other names are moving lower is a sure sign that ADMP, VUZI, and CJJD will remain in their uptrends indefinitely, but it sure doesn't hurt their odds. Here's a closer look at each one and why you'd want to add them to your watchlist.

• [By Roberto Pedone]

   

   

  Another under-$10 drug retailer that's starting to move within range of triggering a big breakout trade is China Jo-Jo Drugstores (CJJD), which operates as a retailer and distributor of pharmaceutical and other health care products in the People's Republic of China. This stock has been on fire for the last three months, with shares ripping higher by 46%.

  If you take a look at the chart for China Jo-Jo Drugstores you'll notice that this stock has been uptrending strong over the last month and change, with shares moving higher from its low of 65 cents per share to its recent high of $1.18 a share. During that uptrend, shares of CJJD have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CJJD within range of triggering a big breakout trade above some near-term and past overhead resistance levels.

  Market players should now look for long-biased trades in CJJD if it manages to break out above some near-term overhead resistance at $1.18 a share and then once it clears some past overhead resistance levels at $1.21 to $1.32 a share high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 99,122 shares. If that breakout hits soon, then CJJD will set up to re-test or possibly take out its next major overhead resistance levels at $1.70 to its 52-week high at $1.99 a share.

  Traders can look to buy CJJD off weakness to anticipate that breakout and simply use a stop that sits just below its 50-day moving average of 98 cents per share. One can also buy CJJD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Asian Companies To Watch For 2015: Hasbro Inc.(HAS)

Hasbro, Inc. engages in the design, manufacture, and marketing of games and toys. The company principally provides children?s and family leisure time and entertainment products and services. It offers various games, including traditional board, card, hand-held electronic, trading card, roleplaying, and DVD games, as well as electronic learning aids and puzzles. Hasbro?s toy products include boy?s action figures, vehicles and playsets, girl?s toys, electronic toys, plush products, preschool toys and infant products, electronic interactive products, creative play products, and toy related specialty products. The company also licenses certain of its trademarks, characters, and other property rights to third parties for use in connection with consumer promotions and for the sale of noncompeting toys and games, and non-toy products. It offers its products primarily under PLAYSKOOL, TRANSFORMERS, NERF, MY LITTLE PONY, LITTLEST PET SHOP, TONKA, G.I. JOE, SUPER SOAKER, MILTON BRAD LEY, PARKER BROTHERS, CRANIUM, AVALON HILL, TIGER, FURREAL FRIENDS, BABY ALIVE, STRAWBERRY SHORTCAKE, and WIZARDS OF THE COAST brand names. The company markets its products to various customers, including wholesalers, distributors, chain stores, discount stores, mail order houses, catalog stores, department stores, and other retailers, as well as Internet-based e-tailers. It has a strategic licensing agreement with Electronic Arts Inc. (EA), which provides EA with the worldwide rights to create digital games for various platforms, including mobile phones, personal computers, and game consoles, as well as; and a strategic relationship with Universal Pictures to produce approximately three motion pictures based on certain of company?s brands. Hasbro sells its products through its own sales force and distributors primarily in the United States, Canada, Mexico, Europe, the Asia Pacific, Latin America, and South America. The company was founded in 1923 and is headquartered in Paw tucket, Rhode Island.

Advisors' Opinion:

• [By Peter Graham]

  The Q3 2014 earnings report for large cap toy stock Mattel, Inc (NASDAQ: MAT), a potential peer of mid cap�Hasbro, Inc (NASDAQ: HAS) and small cap JAKKS Pacific, Inc (NASDAQ: JAKK), is scheduled for before the market opens on Thursday (October 16th). Aside from the Mattel, Inc earnings report, it should be said that Hasbro, Inc will report Q3 2014 earnings on October 20th (Next Monday)�before the market opens while�JAKKS Pacific, Inc will report Q3 2014 earnings before the market opens on October 23rd (Thursday). Mattel, Inc, like other toy stocks, has struggled to remain relevant in an age when many kids prefer to play video, mobile and computer games rather than with physical toys.

• [By Rick Munarriz]

  Mattel's results were merely flat -- and it simply earned less than analysts were targeting instead of shocking the pros with a deficit -- but these gloomy reports can't be comforting for Hasbro (NASDAQ: HAS  ) investors.

10 Best Construction Stocks To Watch For 2016

10 Best Construction Stocks To Watch For 2016: Tutor Perini Corporation(TPC)

Tutor Perini Corporation, together with its subsidiaries, provides diversified general contracting, construction management, and design-build services to private clients and public agencies worldwide. It operates in three segments: Civil, Building, and Management Services. The Civil segment involves in public works construction, and the repair, replacement, and reconstruction of infrastructure. This segment?s civil contracting services include construction and rehabilitation of highways, bridges, mass transit systems, and wastewater treatment facilities. The Building segment provides services to various specialized building markets for private and public works clients, such as the hospitality and gaming, transportation, healthcare, municipal offices, sports and entertainment, education, correctional facilities, biotech, pharmaceutical, industrial and high-tech markets, electrical and mechanical, plumbing, and HVAC services. The Management Services Segment offers diversifie d construction and design-build services to the United States military and government agencies, surety companies, and multi-national corporations in the United States and internationally. This segment also provides rapid response and contract completion services; and management or general contracting services to fulfill the contractual and financial obligations of the surety on notification from the surety of a contractor bond default. The company was founded in 1894 and is headquartered in Sylmar, California.

Advisors' Opinion:

• [By Rich Smith]

  On Wednesday, civil engineering firm Tutor Perini Corp. (NYSE: TPC  ) said the California High-Speed Rail Authority has identified its $985 million bid to design the initial Madera-to-Fresno segment of California's high-speed railway as the "apparent best value" of ! all bids received.

• [By Rich Smith]

  Following up on the news that it's the likely winner of a $985 million contract to design the Madera-to-Fresno segment of California's new high-speed railway, civil engineering firm Tutor Perini  (NYSE: TPC  ) announced Tuesday that it's scored a second major contract win.

source from Top Stocks For 2015:http://www.topstocksblog.com/10-best-construction-stocks-to-watch-for-2016.html

Top Media Companies To Buy For 2016

Top Media Companies To Buy For 2016: DISH Network Corporation(DISH)

DISH Network Corporation, through its subsidiaries, provides direct broadcast satellite (DBS) subscription television services in the United States. It offers programming that includes approximately 280 basic video channels, 60 Sirius satellite radio music channels, 30 premium movie channels, 35 regional and specialty sports channels, 2,800 local channels, 250 Latino and international channels, and 55 channels of pay-per-view content. The company also offers local HD channels in approximately 160 markets and 215 national HD channels; and receiver systems, including a small satellite dish, digital set-top receivers, and remote controls. In addition, it provides DISHOnline.com, which enables DISH Network subscribers to watch 150,000 movies, television shows, clips, and trailers; DISH Remote Access that enables subscribers to remotely manage their DVRs using compatible mobile devices, such as smartphones, tablets, and laptops through their broadband-connected receiver; and Go ogle TV that enables DISH Network subscribers to search the Internet, check email, interact with social media, and find additional online programming content while simultaneously watching television. As of March 31, 2011, the company had approximately 14.191 million customers. DISH Network provides receiver systems and programming through direct sales channels; and independent third parties, such as small satellite retailers, direct marketing groups, local and regional consumer electronics stores, nationwide retailers, and telecommunications companies. The company was founded in 1980 and is headquartered in Englewood, Colorado.

Advisors' Opinion:

• [By Dan Radovsky]

  DISH Network (NASDAQ: DISH  ) will not raise its bid to buy Sprint Nextel (NYSE: S  ) after SoftBank's most recent counteroffer to the satellite TV provider's proposal, DISH announced late yesterday.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-media-companies-to-buy-for-2016.html

Hot High Tech Stocks For 2015

This morning's news that the U.S. economy grew at just a 2.5% rate during the first quarter of 2013 came as an unwelcome reminder that economic growth has been hard to come by lately. With many economies around the world experiencing slowing growth or outright recessionary conditions, an increase in U.S. GDP that fell well short of what economists had expected to see confirmed that the U.S. hasn't been immune from the global malaise. Yet the Dow Jones Industrials (DJINDICES: ^DJI  ) took the news in stride, gaining ground early in the session to gain 12 points as of 10:30 a.m. EDT.

To understand the market's minimal reaction, you have to consider several things. First, the GDP figures released today were merely the first estimate of the nation's economic growth and will be revised two more times before they're finalized. In the fourth quarter of 2012, initial estimates of a decline in GDP were later reversed higher. In addition, investors have actually tended to like relatively weak figures on the economic front because they believe weakness forces the Federal Reserve to maintain its accommodative monetary policies a while longer. And finally, given that the figures are backward-looking, more important forward indicators like the better-than-expected consumer sentiment data released this morning point toward the potential for future gains from the consumer sector.

Top Bank Stocks To Invest In Right Now: JTH Holding Inc (TAX)

JTH Holding, Inc. (JTH Holding), incorporated in September 2010, is a holding company engaged through its subsidiaries as a franchisor and operator of a system of income tax preparation offices located in the United States and Canada. The Company is a retail preparer of individual tax returns. JTH Holding's principal operations are conducted through its subsidiary, JTH Tax, Inc. (JTH Tax). Through this system of income tax preparation offices, JTH Holding also facilitates to its customer refund-based tax settlement financial products, such as refund anticipation loans, electronic refund checks, and personal income tax refund discounting. On September 30, 2010, JTH Tax entered into an Agreement of Merger and Plan of Reorganization with JTH Holding. At the closing of the merger on September 30, 2010, JTH Tax merged with and became a wholly owned subsidiary of JTH Holding.

As of September 2, 2011 (fiscal 2011), the Company had 3,900 tax offices and the number of United States tax returns prepared in its offices is approximately 1.7 million. The Company provides its customers with value-added federal and state tax preparation services and related financial products both in retail offices and online. During fiscal 2011, the Company and its franchisees operated 3,590 offices in the United States in tax season. Approximately 63% of its revenue for fiscal 2011 was derived from franchise fees, royalties and advertising fees. During fiscal 2011, during tax season its online customers prepared approximately 98,000 tax returns using its online tax offering, eSmartTax.

The Company earns franchisee fees from its franchisees and advertisements (Ads). The Company offers its franchisees structures and financing options for franchise fees and royalty payments. The Company earns royalty revenue from its franchisees. Its franchise agreement requires franchisees to pay the Company a base royalty equal to 14% of the franchisee's tax preparation revenue, subject to certain specified minimums. Fran! chisees acquiring territories under its no franchise fee alternative will be required to pay it franchise royalties of 25% through their first five tax seasons, and thereafter 14% of their tax preparation revenue. The Company earns advertising fee revenue from its franchisees. Its franchise agreement requires all franchisees to pay the Company an advertising fee of 5% of the franchisee's tax preparation revenue.

The Company offers two types of financial products: refund transfer products, such as electronic refund checks (ERCs), which involve providing a means by which a customer may receive his or her refund, and refund-based loans, such as refund anticipation loans (RALs) and instant cash advances (ICAs). The Company earns fees from the use of these financial products. The Company also earns tax preparation revenue directly from both the operation of company-owned offices and the provision of tax preparation services through its eSmartTax online product.

Advisors' Opinion:

• [By Dan Caplinger]

  H&R Block (NYSE: HRB  ) will release its quarterly report on Tuesday, and as you'd expect outside of tax season, the tax-preparation company will almost certainly post a sizable loss. But the bigger question investors want answered is whether H&R Block can meet the long-term threat of Intuit (NASDAQ: INTU  ) and its TurboTax software on one end, as well as the live tax-preparation competition of JTH Holdings' (NASDAQ: TAX  ) and its Liberty Tax Service chain.

• [By John Udovich]

  April 15th is tax day and tax preparer stocks like small cap�JTH Holding Inc (NASDAQ: TAX), mid cap�H & R Block Inc (NYSE: HRB) and large cap�Intuit Inc (NASDAQ: INTU) help millions of Americans to figure out just how much they owe to ��ig brother.��But which of these tax preparation stocks is the best investment for investors looking for a way to offset that tax bite? First, here is a quick overview of�each tax preparer:

Hot High Tech Stocks For 2015: Vale SA (VALE5)

Vale SA (Vale) is a Brazil-based metals and mining company. The Company services are divided into four segments: Bulk Material, including the extraction of iron ore, manganese and ferroalloys, as well as pellet production; Basic metals, comprising the production of non-ferrous minerals, including nickel, copper and aluminum; Fertilizers, including the production of potash, phosphate and nitrogen; and Logistic services, including cargo transportation for third parties divided into rail transport, port and shipping services. Additionally, Vale is active in investments in joint ventures and associate in other businesses. The Company operates through subsidiaries and jointly-controlled entities, incorporated in Brazil, Chile, Australia, Canada, Switzerland, Mozambique, Singapore and the USA, among others. In December, 2013, the Company sold Sociedad Contractual Minera Tres Valles to Inversiones Porto San Giorgio SA. In December 2013, it sold entire stake in Log-in Logistica Intermodal SA. Advisors' Opinion:

• [By Ney Hayashi]

  Iron-ore producer Vale SA (VALE5) may be active after agreeing to pay 22.3 billion reais ($9.6 billion) to settle a tax dispute with Brazil over profits at its foreign units. Meatpacker Minerva SA may move after Russia lifted a ban on beef exports from one of its plants.

• [By Zahra Hankir]

  The MSCI Emerging Markets Index advanced 0.2 percent to 1,044.66. The Ibovespa jumped to the highest level since March 18 as iron-ore producer Vale SA (VALE5) rallied, while AngloGold Ashanti Ltd. drove the FTSE/JSE Africa All Shares Index to a record in Johannesburg. South Africa�� rand jumped to a one-month high, pacing gains among 24 developing-nation currencies.

• [By Harry Suhartono]

  The Ibovespa dropped 1.8 percent as iron-ore producer Vale SA (VALE5), whose main export market is China, snapped a two-day gain. Pulp producer Fibria Celulose SA (FIBR3) retreated after posting quarterly earnings that trailed analysts��estimates. Brazil plans to sell dollar bonds due in 2025, creating a new benchmark security in international markets, and buy back notes maturing in as little as four years.

• [By Ney Hayashi]

  MSCI Inc. gauges of Brazilian energy and raw-materials companies, including Rio de Janeiro-based Petroleo Brasileiro SA (PETR4) and Vale SA (VALE5), have tumbled at least 16 percent in local currency terms in the past 12 months as the S&P GSCI Spot Index of commodities slid 8.9 percent.

Hot High Tech Stocks For 2015: Spectrum Rare Earths Ltd (SPX)

Spectrum Rare Earths Limited, formerly TUC Resources Ltd, is engaged in the exploration and evaluation of rare earths, uranium, base metals and gold mineral interests. On October 2, 2012, holds approximately 18,000 square kilometer of prospective land package across 44 tenements. During the fiscal year ended June 30, 2011, the Company is focuses on its Stromberg Heavy Rare Earth Project. The Company has 50, 100% owned tenements in the Northern Territory. Tenements within the Pine Creek Project consist of EL's 24884, 25224, 25228 and uranium rights on EL24906. Parts of EL24906 and EL24884 are located within the Rum Jungle Mineral Field. The Arnhem Project encompasses all the Company�� tenement holdings in the East Alligator River region within 150 kilometer of the high grade Narbalek uranium mine. The Litchfield Uranium Project consists of granted licenses EL25195 and EL25176 and license applications 25472, 25473 and 25221. Advisors' Opinion:

• [By Wallace Witkowski]

  Big banks are expected to bust out some of the best bottom-line results of the season, and a lot of those come out this week. Of the 25 companies on the S&P 500 Index (SPX) �that are scheduled to report quarterly earnings this week, 17 belong to the financial sector. Half the six Dow Jones Industrial Average (DJIA) �components reporting this week are financial firms.

• [By Alex Barinka]

  The Standard & Poor�� 500 Index (SPX) will climb 8 percent to 1,825 in the next 12 months as economic growth gains momentum, according to Goldman Sachs Group Inc.

• [By Richard Moroney]

  DOW trades at 20 times trailing earnings, 14% above the average diversified-chemical company in the S&P 500 Index (SPX) . But consensus estimates project per-share profits will rise 18% this year and next year, and DOW trades at a discount to peers based on cash flow. The stock is rated Buy and Long-Term Buy.

• [By Noah Buhayar]

  The divide is widening between Birinyi, whose bullish forecasts have proved prescient during a 4 1/2-year bull market, and Einhorn, who gained fame betting against Lehman Brothers Holdings Inc. Stocks in the U.S are in the midst of their broadest advance on record, a rally that has burned short sellers and pushed valuations to the highest levels since 2010 as the S&P 500 (SPX) reaches all-time highs.

Hot High Tech Stocks For 2015: Apricus Biosciences Inc(APRI)

Apricus Biosciences, Inc. engages in the design and development of pharmaceutical products and product candidates based on its patented NexACT drug delivery technology. The NexACT drug delivery technology is designed to enhance the delivery of an active drug to improve therapeutic outcomes and reduce systemic side effects that accompany existing oral and injectable medications. The company?s pipeline includes Vitaros, approved in Canada for the treatment of erectile dysfunction; and Totect approved in the U.S. for the treatment of anthracycline extravasation, as well as compounds in development from pre-clinical through pre-registration, focused on sexual dysfunction, oncology, dermatology, autoimmune, pain, anti-infectives, diabetes, and consumer healthcare. The company was founded in 1987 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Eric Volkman]

  Apricus Biosciences (NASDAQ: APRI  ) is hoping to widen its capital base significantly. The company is floating a mix of common stock and warrants that it hopes will raise net proceeds of nearly $16 million. Six million shares will be sold in an underwritten public offering at $2.85 apiece, and 3 million warrants will be issued separately at an exercise price of $3.40 per share.�

• [By Jon C. Ogg]

  Apricus Biosciences Inc. (NASDAQ: APRI) was initiated with a Hold rating and a $2 price target at Cantor Fitzgerald. Be advised that $2 is almost 10% under the prior close of $2.18, against a 52-week range of $1.89 to $3.49.

• [By John Udovich]

  On Friday, small cap pharma stock Apricus Biosciences Inc (NASDAQ: APRI) jumped just over 10% and not only�did the stock hold onto those gains, it made�another 10% jumps on Monday���meaning its time to take a closer look at the stock along with the performance of other potential benchmarks in the sexual health or reproductive health spaces like The Female Health Company (NASDAQ: FHCO) and Repros Therapeutics Inc (NASDAQ: RPRX).

Best Chemical Stocks To Invest In 2016

Best Chemical Stocks To Invest In 2016: Cytec Industries Inc (CYT)

Cytec Industries Inc/De/, formerly Cytec Industries Inc., incorporated on December 17, 1993, is a specialty chemicals and materials company focused on developing, manufacturing and selling value-added products. Its products serve a diverse range of end markets, including aerospace and industrial materials, mining and plastics. The Company has four business segments: Engineered Materials, Umeco, In-Process Separation and Additive Technologies. Engineered Materials segment principally includes advanced composites, carbon fiber, and structural film adhesives. The Umeco segment includes composite and process materials, primarily for the aerospace and defense, wind energy, automotive, recreation and other industrial segments. The In Process Separation segment includes mining chemicals and phosphines. The Additive Technologies segment includes polymer additives, specialty additives and formulated resins. On July 20, 2012, the Company acquired Umeco plc.

Engineered Materials

The Engineered Materials segment is a global provider of technologically advanced materials for aerospace, high-performance industrial and other extreme-demand markets. Its primary product lines are advanced aerospace composites and structural adhesives, High performance industrial materials and Carbon fibers. Its major products in the advanced aerospace composites include aerospace- qualified prepregs, resin infusion systems and structural/surfacing adhesives. Its principal applications include commercial airliners, regional and business jets, military aircraft, including rotorcraft, satellites and launch vehicles. The products in the high performance industrial materials include Industrial-grade prepregs, resin infusion systems and structural/surfacing adhesives. Its applications include high performance automotive, defense, tooling and alternati! ve energy. The products in carbon fibers include high performance fiber carbon fibers. Its applications in clude reinforcements for advanced aerospace and industrial c! omposites.

The Company is a supplier to the F-35 Joint Strike Fighter and F-18 fighter jet programs. It is also a supplier for the business and regional jet market, supporting programs, such as Bombardier's CSeries and LearJet85. It also manufactures specialty adhesive forms for complex composites assemblies, such as honeycomb and sandwich structures and special surfacing films to provide aircraft lightning strike protection. It manufactures and sells various high-performance grades of both polyacrylonitrile (PAN) type and pitch type carbon fibers used as a reinforcement material for aerospace and other extreme-demand and high-performance composites.

The Company's High Performance Industrial Materials (HPIM) product line strategy is to leverage its composites, adhesives and resin technologies across multiple industrial markets. The Company supplies composites and adhesives to a spectrum of markets, such as high performance and luxury low-rate s erial automotive, defense, and alternative energy.

Umeco

Umeco's primary product lines are High performance composites structural materials/solutions and Composite process materials/solutions. Its major products in the High performance composites structural materials/solutions include Aerospace-qualified prepregs, Industrial-grade prepreg. Its principal applications include large commercial airliners, military aircraft, high performance automotive, defense, tooling, recreation, industrial and alternative energy. The products in Composite process materials/solutions include Process materials/solutions including vacuum bagging, release films and sealant tapes. Its principal applications include large commercial airliners, military aircraft, high performance automotive, defense, tooling, recreation, industrial and alternative energy and ! Process m! aterials for the forming, infusion, curing of composite structures.

The Company's struct ural materials product line includes the development, manufa! cturing a! nd supply of advanced composite materials. It specializes in the manufacture of composite materials for a range of industries such as aerospace and defense, marine, motor sport and automotive, construction, wind energy, and recreation.

In-Process Separation

The In-Process Separation segment includes mining chemicals and phosphines. The Company's mining chemicals product line include flotation promoters, collectors, frothers, dispersants and depressants, solvent extractants, flocculants, filter and dewatering aids, antiscalants, and defoamers . Its principal applications include mineral separation and processing for copper, alumina, cobalt, nickel, and other minerals. Its Phosphines include flame retardants, catalyst ligands, high purity phosphine gas and biocides.

Its phospine based specialty products are used primarily in the pharmaceutical, chemical and electronic manufacturing, and fumigation. Its patented MaxHT antiscalant is so ld for suppressing sodalite scale formation. Its phosphine specialties are utilized for a variety of applications. It is a supplier of ultra- high purity phosphine gas, used in semiconductor manufacturing and light emitting diode applications, various phosphine derivative products, including phosphonium salts used in pharmaceutical catalysts and biocides. Included in the phosphine line are organo phosphorus compounds. The compounds are used primarily as intermediates and catalyst ligands for organic and chemical synthesis in the pharmaceutical and chemical industries.

Additive Technologies

The Additive Technologies segment includes polymer additives specialty additives and Formulated resins. Polymer additives include ultraviolet light stabilizers and absorbers, high performance antioxidants and antistatic agents. Its application! s include! plastics, coatings, and fibers for: agricultural films, automotive parts, architectural lighting, housewares, pac kaging, outdoor furniture, sporting goods, toys and apparel.! Specialt! y additives include surfactants, specialty monomers, resin amines, and PTZ Phenothiazine. Its Formulated resins are used in for bonding or sealing of electrical and electronic components.

The Company markets its Additive Technologies chemicals through specialized sales and technical service staffs for each of its product lines. Sales are usually made directly to customers and through distributors to smaller customers. The Company is a global supplier to the plastics industry of specialty additives, which protect plastics from the ultraviolet radiation of sunlight and from oxidation. It is a global supplier of sulfosuccinate surfactants, Docusate sodium, and PTZ phenothiazine. Sulfosuccinate surfactants and acrylamide-based specialty monomers products are used in emulsion polymers, paints, paper coatings, printing inks, and other diverse customer applications. Docusate is a pharmaceutical grade product used as both an active ingredient and excipient/formulating a id. PTZ phenothiazine is primarily used as an acrylic acid, acrylic ester and methacrylate monomer stabilizer.

Advisors' Opinion:

• [By alicet236]

  Vice President and CFO of Cytec Industries Inc. (CYT) David Drillock sold 49,038 shares on July 21 at an average price of $107.06. The total transaction amount was $5,250,008.

• [By Stoyan Bojinov]

  The New Jersey-based specialty chemicals maker, Cytec Industries (CYT), announced third quarter operating results after the closing bell on Thursday that topped analysts’ estimates.

  Cytec Industries managed to rake in revenues of $464 million last quarter, falling short of the projected $482.61 million figure. The company did manage to beat the mark, however, in terms of earnings per share; in the third quarter Cytec generated EPS of $1.32, b! eating th! e expected EPS of $1.34 by two pennies.

  Looking back, the most recent quarterly results are well above the 91 cents EPS seen in Q3 exactly one year ago. Looking ahead, the company expects FY2013 EPS of $4.70-$4.80 compared to the consensus of $4.82.

  Cytec Industries shares rallied higher on Thursday, gaining 0.58% on the day. The stock is up 25% YTD.

• [By Rich Duprey]

  Specialty chemicals and materials maker Cytec Industries  (NYSE: CYT  ) announced this morning that it will be completing its previously authorized $650 million share repurchase program that it had announced last October, and the board of directors has authorized a new $200 million buyback plan.

source from Top Stocks For 2015:http://www.topstocksblog.com/best-chemical-stocks-to-invest-in-2016.html

Opening Print and S&P Levels to Watch

Global stocks, shares, bonds and currencies all surged, with algorithm and program trading driving the orders after yesterday's surprise decision by the U.S. Federal Reserve not to curtail its asset-buying program. As the Federal Reserve headlines hit the tape the trading pits of the CME Group's financial room exploded, hitting out buy stops in both the index and interest rate futures and options. Algorithmic and program trading takes up so much space in the futures markets that tools that used to work don't anymore. The program writers have figured out every tool we use, even the plus or minus 1000 -1300 ticks and the new indicators (if they work) don't last very long. If it's not tied to an algorithm you can forget it .That means that traders to constantly be looking for a new edge. Whether its learning "pivots and vol windows" or learning how to read the program levels in the S&P. As for today we have eight economic numbers , some Fed speak and the last day of the September rollover. With all the talk of the Fed most people have not paid much attention to this Friday's September Quadruple Witching. While it is no way the event that it used to be it still needs to be on your radar. Accordingly, the Ned Davis S&P cash study shows pre-expiration Thursday was up 16 and down 13 of the last 29 occasions; expiration Friday up 17 / down 12 of the last 29 occasion and next Monday (or the first trading day after the expiration ) up 9 / down 20 of the last 29. Our view: The S&P futures have rallied to 1725, a full 100 handles from their 1625 taper low. Additionally, the S&P futures have closed higher eight out of the last nine session, or up four in a row. Provided the economic reports don't surprise and knowing the S&P is the global leader it may be rest time for the ESZ. As firm as the S&P acts the futures have gone 85 handles in the last 11 days. After a big day up like yesterday and knowing the news is out we lean to a side ways to lower S&P today. Not saying the S&P can't or won't rally, but we think it will sell off a bit today. As always, use stops and keep an eye on the 10-handle rule. Don't forget to catch MrTopStep on The Closing Print video. We report directly from the SPX pits, wrapping up the day and positioning for trade tomorrow. OptionsProfits can be followed on Twitter at twitter.com/OptionsProfits MrTopStep can be followed on Twitter at twitter.com/MrTopStep For LIVE futures chat, more information on the 10-handle rule and futures educational content CLICK HERE FOR A SEVEN-DAY FREE TRIAL.

Top 5 Trucking Companies To Buy Right Now

Top 5 Trucking Companies To Buy Right Now: Royal Caribbean Cruises Ltd.(RCL)

Royal Caribbean Cruises Ltd. operates in the cruise vacation industry worldwide. It owns five cruise brands, which comprise Royal Caribbean International, Celebrity Cruises, Pullmantur, Azamara Club Cruises, and CDF Croisires de France. The Royal Caribbean International brand provides various itineraries and cruise lengths with options for onboard dining, entertainment, and other onboard activities primarily for the contemporary segment. It offers surf simulators, water parks, ice skating rinks, rock climbing walls, and shore excursions at each port of call, as well as boulevards with shopping, dining, and entertainment venues. The Celebrity Cruises brand operates onboard upscale ships that offer luxurious accommodations, fine dining, personalized services, spa facilities, venue featuring live grass, and glass blowing studio for the premium segment, as well as resells computers and other media devices. The Pullmantur brand provides an array of onboard activities and serv ices to guests, including exercise facilities, swimming pools, beauty salons, gaming facilities, shopping, dining, complimentary beverages, and entertainment venues serving the contemporary segment of the Spanish, Portuguese, and Latin American cruise markets. The Azamara Club Cruises brand offers various onboard services, amenities, gaming facilities, fine dining, spa and wellness, butler service for suites, and interactive entertainment venues for the up-market segment of the North American, United Kingdom, German, and Australian markets. The CDF Croisieres de France brand offers seasonal itineraries to the Mediterranean; and various onboard services, amenities, entertainment venues, exercise and spa facilities, fine dining, and gaming facilities for the contemporary segment of the French cruise market. As of December 31, 2011, the company operated 39 ships with a total capacity of approximately 92,650 berths. Royal Caribbean Cruises Ltd. was fou! nded in 1968 and is headqua rtered in Miami, Florida.

Advisors' Opinion:

• [By Caroline Bennett]

  Royal Caribbean Cruises (NYSE: RCL  ) has signed a contract with shipyard Meyer Werft to begin building a new Quantum-class cruise ship, its third such vessel, the company announced today. The ship is scheduled for delivery during the middle of 2016.

• [By Monica Wolfe]

  Royal Caribbean Cruises (RCL)

  Chairman and CEO Richard Fain has made the largest insider buy this week, buying nearly one million dollars worth of shares.

• [By Rick Munarriz]

  This is a dinner bell for Carnival's smaller rivals. Royal Caribbean (NYSE: RCL  ) is introducing its latest vessel -- Quantum of the Seas -- this week. Online chatter claims that Disney (NYSE: DIS  ) is about to expand its growing fleet by 50% when it announces two new ships later this month.(A Disney spokeswoman claims that new ships won't be announced at next week's media event, but there's clearly excitement about the cruise industry outside of Carnival.)

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-trucking-companies-to-buy-right-now.html

Top 10 New Companies To Buy Right Now

Top 10 New Companies To Buy Right Now: Aventine Renewable Energy Holdings Inc (AVRW)

Aventine Renewable Energy Holdings, Inc. (Aventine) is engaged in marketing and distributing ethanol to energy and trading companies in the United States. In addition to producing ethanol, the Company's facilities also produce several by-products, such as distillers grain, corn gluten meal and feed, corn germ and grain distillers dried yeast. During the year ended December 31, 2011, the Company's facilities had a combined total ethanol production capacity of approximately 312 million gallons annually with corn processing capacity of approximately 115 million bushels.

The Company's principal product is fuel-grade ethanol, an alcohol,l which is derived in the United States principally from corn. Ethanol is sold primarily for blending with gasoline to meet mandates for the required consumption and use of biofuels, as an octane enhancer, as an oxygenate additive for the purpose of meeting fuel emission standards and as a fuel extender.

The Comp any is also engaged in the sale of by-products, both co-products and bio-products, which result from the ethanol production process. The volume of by-products it produces varies with the level of the Company's equity production. Scheduled maintenance, along with other non-scheduled operational difficulties, affects the volume of by-products produced. The Company also shift the mix of these by-products.

The Company's Illinois wet mill facility produces co-products, such as corn gluten feed (both wet and dry), corn gluten meal, corn distillers with soluble (CCDS) and corn germ. In addition, the fermentation process yields carbon dioxide. The Company's dry mill facilities in Pekin, Illinois, Mt. Vernon, Indiana and Aurora, Nebraska produce co-products, such as DDGS, wet distillers grains with soluble and carbon dioxide. These co-products! are sold for various consumer uses into commodity markets. Corn gluten feed, corn gluten meal, CCDS and distillers grains are used as animal feed ingredients, corn germ is sold for t! he extraction of corn oil for human consumption, and carbon dioxide is sold for food-grade use, such as beverage carbonation and dry ice. Along with co-products, its Illinois wet mill facility also produces bio-products, Kosher and Chametz freegrain distillers dried yeast, which is processed into a growing variety of products for use in animal and human food and fermentation applications.

Advisors' Opinion:

• [By Johanna Bennett]

  Pacific Ethanol (PEIX) rose almost 6% after it agreed to buy Aventine Renewable Energy (AVRW) Holdings Inc. for about $190 million in stock. Aventine jumped 11.5% on the news.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-new-companies-to-buy-right-now-3.html

Top 5 Restaurant Companies For 2016

Top 5 Restaurant Companies For 2016: Country Style Cooking Restaurant Chain Co Ltd (CCSC)

Country Style Cooking Restaurant Chain Co., Ltd. (CSC Cayman), incorporated on August 14, 2007, is a quick service restaurant chain in China. The Company offers delicious, everyday Chinese food. The Company conducts all of its restaurant operations through CSC China and its subsidiaries. As of June 30, 2012, it had 256 restaurants, including 124 restaurants in Chongqing municipality and 85 restaurants in Sichuan province.

Chongqing municipality and Sichuan province cover a region of 110 million people in Southwest China. CSC Cayman directly operates all of its restaurants. Its standard menu features its main dishes prepared in the Sichuan style, as well as a selection of other dishes, appetizers, desserts and beverages. The Company periodically offers new dishes and seasonal menu selections.

The Company competes with McDonald's, KFC and Yoshinoya.

Advisors' Opinion:

• [By CRWE]

  Country Style Cooking Restaurant Chain Co., Ltd (NYSE:CCSC), a fast-growing quick service restaurant chain in China, plans to release its unaudited second quarter 2012 financial results on Tuesday, August 14, 2012, after the market closes.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-restaurant-companies-for-2016.html

Hot Medical Stocks To Invest In Right Now

Cyndi Takacs went the extra miles last year to earn additional paid time off, and she plans to do the same this year.

She and other employees at Excelas, a medical consulting firm with 44 staffers in Cleveland, get one extra hour of paid time off for every 33,000 steps they take during the first three months of the year, for up to three extra days of paid leave.

To meet the goal last year, she did laps around the parking lot at lunch, and she took the dogs out for an extra walk at night. "Earning time off with pay is a great motivator to get me moving," says Takacs, the company's office coordinator. Excelas also makes charitable donations based on the employees' walking milestones.

The walking program is part of the company's wellness initiative, which also includes nutrition and stress-reduction programs. "The immediate objective is to improve the health of the staff," says Jean Bourgeois, the company's president and founder. "If our programs lead to a reduction in our health care costs over time, as we believe they will, that's the end game that benefits our company as a whole."

Top 10 Electric Utility Companies To Own In Right Now: Neuroderm Ltd (NDRM)

Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson�� disease (PD). The Company designs product candidates that address needs in the field of Parkinson�� disease and cognition. The Company�� product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. The Company developed a liquid formulation of levodopa/carbidopa (LD/CD). The Company through its reformulation technology develops a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. The Company�� LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson�� disease.

ND0612L for moderate Parkinson�� disease

ND0612L is under development for the treatment of moderate Parkinson�� disease patients who can no longer effectively control their motor complications with oral levodopa. ND0612L is developed as a fixed dose liquid formulation of levodopa and carbidopa to be administered subcutaneously, over a day and night period. The product ND0612L has two versions under development: ND0612L belt pump version, which is subcutaneously administrated via a small belt-pump, and ND0612L Patch Pump Version, which is a second generation product that is subcutaneously administrated via a patch pump.

The Company has conducted two Phase I studies and a Phase IIa clinical study with N0612L. The clinical studies was a single-dose, 24-hour continuous-administration, randomized, double-blind, placebo-controlled study on eight subjects with moderate Parkinson�� disease. The study results demonstrated that subcutaneous deli! very of ND0612L was safe and tolerable, and achieved steady-state plasma levodopa concentrations of 700-900 nanogram/milliliter. Additionally, administration of ND0612L was shown to significantly reduce fluctuations in plasma levodopa concentrations.

The Company is conducting a Phase II randomized, placebo-controlled, double-blind study of ND0612L on approximately 30 Parkinson�� disease patients suffering from motor complications. The study�� primary endpoints are safety and tolerability, as well as the pharmacokinetic profile of levodopa plasma concentrations.

ND0612H for severe Parkinson�� disease

The Company is developing ND0612H for the treatment of severe-stage Parkinson�� disease patients for whom oral drugs are no longer effective. The ND0612H belt pump (CRONO Twin ND) is a drug pump that delivers levodopa/carbidopa (LD/CD) to treat severe Parkinson�� disease patients. ND0612H provides continuous subcutaneous delivery of an adjustable, high dose, LD/CD formulation to improve motor and non-motor complications in patients refractory to oral LD/CD. ND0612H�� is subcutaneously administrated utilizing a belt-pump allowing patients to receive continuous LD/CD therapy round the clock. The Company is conducting Phase II clinical trials on the product ND0612H for the treatment of severe-stage Parkinson�� disease.

ND0680 for severe Parkinson�� disease

ND0680 is indicated for the treatment of very severe Parkinson�� disease, which requires high doses of LD/CD which cannot be provided via oral delivery or using ND0612L and ND0612H. ND0680 is administered via a tube to the duodenum. ND0680 formulation contains a much higher concentration of LD/CD and is administered with the CRONO ND belt pump via the duodenum. The Company is conducting Phase I clinical trials for the development of ND0680

ND0701 for severe Parkinson�� disease

ND0701 is an apomorphine-based product candidate. ND0701 is desi! gned for ! the treatment of patients with severe Parkinson�� disease and do not respond well to LD/CD. ND0701 is administered via a CRONO ND belt pump or a patch pump (1st and 2nd generation, respectively). The Company is conducting Phase I clinical trials for the development of ND0701 indicated for the treatment of severe Parkinson�� disease.

ND0801 for Cognitive Disorders

ND0801 is under development for the treatment of cognition disorders associated with central nervous system diseases, such as Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer�� disease, Parkinson�� disease and schizophrenia. ND0801�� is covered by a reformulation and is designed to be a nicotine-based combination drug treatment. ND0801 is administered via a transdermal patch.

The Company is conducting tests on ND0801 for the treatment of ADD/ADHD in two centers in Israel in an open-label, Phase IIa, proof-of-concept dose escalation study on approximately 45 adult patients. The study is designed to demonstrate the safety, tolerability and optimal therapeutic doses of ND0801, and evaluate the cognitive improvement in subjects following treatment with escalating doses of ND0801. Interim results from 30 patients enrolled have demonstrated a dose dependent improvement in attention and cognition following seven days of ND0801 treatment with no observed serious side effects.

Advisors' Opinion:

• [By Johanna Bennett]

  NeuroDerm (NDRM) nearly doubled in value today, rising to $12.25 a share after more than 15 million shares changed hands, after the company reported positive results in a small trial for a treatment for Parkinson�� disease.

Hot Medical Stocks To Invest In Right Now: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By John Udovich]

  Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

• [By John Udovich]

  The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

• [By Bryan Murphy]

  If you're reading this, then odds are you already know that the last two weeks (not even a full two weeks) have been more fruitful for Cell Therapeutics Inc. (NASDAQ:CTIC) shareholders than the prior two years have been - the stock's up 28% since last Thursday. And, odds are you already know why. The question most of you are asking now is, can CTIC actually keep climbing at this pace, or even keep climbing at any pace? The answer is "yes", though floating that answer almost inherently requires a deeper explanation.

Hot Medical Stocks To Invest In Right Now: Clovis Oncology Inc (CLVS)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.

CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Advisors' Opinion:

• [By James E. Brumley]

  Cancer drug investors who have been disappointed in recent results from shares of Clovis Oncology Inc. (NASDAQ:CLVS) or Nuvilex Inc. (OTCMKTS:NVLX) lately may want to take a look at ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as a replacement for either of those first two stocks. CLVS is down about 16% for the week on a less-than-flattering write-up in a Bloomberg publication, and NVLX has moved under a pair of key moving averages this week because, well, for no specific reason, but broadly because the recent wave of compelling news is already losing its potency, with most of that upside already being priced into shares (and then some) before it became official.

• [By Jake L'Ecuyer]

  Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.

Hot Medical Stocks To Invest In Right Now: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:

• [By Tim Brugger]

  After confirming an unsolicited takeover bid from privately held investment firm Royalty Pharma in late February, Ireland-based Elan (NYSE: ELN  ) announced today that its board has unanimously rejected the offer.

Hot Medical Stocks To Invest In Right Now: Cerner Corp (CERN)

Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT) solutions, services, devices and hardware. Cerner solutions optimize processes for healthcare organizations. These solutions are licensed by approximately 9,300 facilities globally, including more than 2,650 hospitals; 3,750 physician practices 40,000 physicians; 500 ambulatory facilities, such as laboratories, ambulatory centers, cardiac facilities, radiology clinics and surgery centers; 800 home health facilities; 40 employer sites and 1,600 retail pharmacies. The Company operates in two segments: domestic and global. The domestic segment includes revenue contributions and expenditures associated with business activity in the United States. The global segment includes revenue contributions and expenditures linked to business activity in Argentina, Aruba, Australia, Austria, Canada, Cayman Islands, Chile, China (Hong Kong), Egypt, England, France, Germany, Guam, India, Ireland, Italy, Japan, Malaysia, Morocco, Puerto Rico, Qatar, Saudi Arabia, Singapore, Spain, Sweden, Switzerland and the United Arab Emirates. On May 23, 2011, the Company acquired Resource Systems, Inc. On October 17, 2011, the Company acquired Clairvia, Inc. Effective March 18, 2013, it acquired Labotix Automation Inc.

The Company designs and develops software solutions on the unified Cerner Millennium architecture, a person-centric computing framework, which combines clinical, financial and management information systems. This architecture allows providers to access an individual�� electronic health record (EHR) at the point of care, and it organizes and proactively delivers information to meet the specific needs of physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals and consumers. It also offers a range of services, including implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, healthcare data analysis, clinical proc! ess optimization, transaction processing, employer health centers, employee wellness programs and third party administrator (TPA) services for employer-based health plans.

The Company offers a longitudinal, person-centric EHR, which gives clinicians electronic access to the right information at the right time and place to achieve optimal health outcomes. Medical information and care regimens accessible from home enables consumers to manage their conditions and adhere to treatment plans, creating a medium between physicians and individuals. Its Cerner ITWorks is a suite of services, which creates an alignment between Cerner and its clients. Its Cerner RevWorks includes solutions and services to help healthcare organizations improve their revenue cycle functions. It offers clinic, pharmacy and wellness services directly to employers.

The Company's Healthe Intent Chart Search includes clinical meanings of words located within the electronic medical record (EMR), as well as the context in which those words occur to create algorithms that identify and rank information contextually. The Healthe Intent platform also provides the ability to apply algorithms against contextual clinical activity to recommend clinical action.

The Company competes with Allscripts Healthcare Solutions, Inc., Computer Programs and Systems, Inc. (CPSI), Epic Systems Corporation, GE Healthcare Technologies, Healthcare Management Systems, Inc. (HMS), Healthland, Inc., Computer Sciences Corporation (iSoft), Keane, Inc., McKesson Corporation, Medical Information Technology, Inc. (Meditech), Siemens Medical Solutions Health Services Corporation, Quadramed Corporation, Accenture plc, Affiliated Computer Services (ACS), Cap Gemini S. A., Computer Task Group, Inc. (CTGHS), Dell, Inc., Deloitte Consulting LLP, Hewlett-Packard Company, IBM Corporation, maxIT Healthcare LLC, AmazingCharts.com, Inc., Athenahealth, Inc., eClinicalWorks LLC, e-MDs, Inc., Greenway Medical Technologies, MED3000, Inc., Quality Sy! stems, In! c., Conceptual MindWorks, Inc., Vitera Healthcare Solutions, API Healthcare, CapsuleTech, Inc., CareFusion Corporation, GE Healthcare Technologies, iSirona, LLC, McKesson Corporation, Omnicell, Inc., Accretive Health, Inc., Capario, Inc., Emdeon Corporation, McKesson Corporation, MedAssets, Inc., Optum, Inc., SSI Group, Inc. and 3M Company.

Advisors' Opinion:

• [By Lu Wang]

  Cerner (CERN) Corp. rallied 8 percent, the most in the S&P 500, to a record $52.61. The provider of electronic medical records said it reached a multiyear agreement to provide services to Intermountain Healthcare.

• [By Keith Speights]

  Cerner (NASDAQ: CERN  ) stands out as another big beneficiary of the government's helpful hands. In March 2009, the big EHR vendor reported revenue of $1.67 billion. By the end of last year, Cerner's revenue had jumped to over $2.66 billion.

• [By James E. Brumley]

  Truth be told, it's not clear if SK3 Group Inc. (OTCMKTS:SKTO) is best described when compared to a name like Cerner Corporation (NASDAQ:CERN), or to a Gentiva Health Services, Inc. (NASDAQ:GTIV). The company's got elements of both major industries being represented by CERN and GTIV (home health care, and information technology), with the addition of another budding industry thrown into the mix. One thing IS clear though... SKTO shares have decidedly reversed a nasty downtrend, and may now be one of the market's best small cap healthcare speculative trades.

• [By Susan J. Aluise]

  Another positive: Florida’s Agency for Health Care Administration chose MGLN to administer its Medicaid specialty plan for individuals with serious mental illness. The program will be implemented in eight regions throughout Florida and in 40 of its 67 counties. Right now, MGLN stock has a forward P/E of about 19 — roughly average for healthcare stocks.

  Healthcare Stocks: Cerner (CERN)

  When it comes to achieving success with the Affordable Care Act, don’t underestimate the power of information technology to help or hinder the progress. Given the disastrous technical problems that attended last fall’s launch, the heat is on all parties to ensure that the technology works as advertised.

Hot Medical Stocks To Invest In Right Now: SearchCore Inc (SRER)

SearchCore, Inc., formerly General Cannabis, Inc., incorporated in 2003, is a technology service provider. As of December 31, 2011, the Company was engaged in the medicinal cannabis industry. The Company assists the physicians, dispensaries, and end-users within the medicinal cannabis industry in finding each other and in advertising their businesses. All of its operations are conducted through its wholly owned subsidiaries. On January 5, 2012, WeedMaps, LLC (WeedMaps) acquired substantially all the assets of MMJMenu, LLC. On October 31, 2011, General Merchant Solutions, Inc. discontinued all retail credit card processing operations. On January 11, 2011, the Company acquired all the assets of Revyv, LLC. On December 31, 2012, the Company acquired Sports Asylum, Inc. In February 2013, it acquired ModularHomes.com.

WeedMaps Media, Inc. is its wholly owned subsidiary, and its primary operation is the Internet Website, www.weedmaps.com. WeedMaps.com is an online finder site service that allows patients to find local medical cannabis dispensaries, which are also referred to as collectives. Dispensaries are locations where patients who have received letters of recommendation from a healthcare provider can purchase medicinal cannabis, as well as a variety of other non-cannabis related items including, but not limited to, apparel accessories, posters, bumper stickers, concert tickets, books and musical compact disc�� (CD��).

General Marketing Solutions, Inc. is its wholly owned subsidiary, and its primary operation is the Internet Website, www.cannabiscenters.com. General Management Solutions, Inc. is its wholly owned subsidiary that oversees and provides all of the human resources issues for employees, including hiring, terminating and employee benefits. The Company has two additional wholly owned subsidiaries; General Processing Corporation, CannaCenters Corporation (CannaCenters), and two subsidiaries, namely LV Luxuries Incorporated (which operated as makeup.com) and General ! Health Solutions, Inc. (CannaCenters.com).

Advisors' Opinion:

• [By Peter Graham]

  Small cap communications or Internet stocks American Community Development Group Inc (OTCMKTS: ACYD), Globalstar, Inc (OTCMKTS: GSAT) and SearchCore Inc (OTCMKTS: SRER) have been rather quiet lately for investors after making some noise back in September. Nevertheless, all three are still getting some mentions in various investment newsletters or alerts and not because they are the subject of paid promotions. So are these small cap stocks about to make some noise? Here is a closer look: